Heterodimeric fc cytokines and uses thereof
AssigneeSynthekine, Inc.
InventorsPatrick Lupardus, Deepti Rokkam
Life of this patent
Estimating the term…
Abstract
The present disclosure provides IL12 and IL23 muteins as partial agonists comprising modified human p40 molecules that associate with human p35 (hP35) and human P19 (hP19) to form modified hIL-12 and IL23 partial agonists wherein the individual components of IL12 and IL23 muteins are linked to engineered Fc domains.
Claims10
-88. (canceled)
A pharmaceutically acceptable formulation comprising as an active ingredient a heterodimeric hIL12Fc mutein comprising:
- a first polypeptide comprising SEQ ID NO:
- 129;
- and
- a second polypeptide comprising SEQ ID NO:
- 124.
A method of treating a human suffering from a neoplastic disease, the method comprising contacting the human with the pharmaceutically acceptable formulation of claim 1.
Dependencies are inferred from the claim text.